Shopping Cart 0
Cart Subtotal
AED 0

Synairgen Plc (SNG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-/SNG001) for asthma in Phase II trial; and IFN- (SNG001) for COPD in Phase I trial. The company develops its drugs based on its BioBank platform technology. Its BioBank comprises blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma and COPD. The company uses these resources to develop in vitro and ex vivo models, which can be used for discovering novel drug targets. It discovers and develops the drug targets through early stages and out-licenses them to other pharmaceutical companies for further development and manufacturing. Synairgen is headquartered at Southampton, the UK.

Synairgen Plc (SNG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Synairgen Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Synairgen Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Synairgen Plc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Pharmaxis Expands Agreement with Synairgen 10

Licensing Agreements 11

AstraZeneca Enters into Licensing Agreement with Synairgen for SNG001 11

Equity Offering 13

Synairgen to Raise USD3.7 Million in Private Placement of Shares 13

Synairgen Raises USD9 Million in Private Placement of Shares 15

Synairgen Announces Private Placement Of Shares For USD 2.5 Million 17

Synairgen Completes Private Placement Of Shares For USD 4 Million 18

Synairgen Plc-Key Competitors 19

Synairgen Plc-Key Employees 20

Synairgen Plc-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Recent Developments 22

Financial Announcements 22

Sep 25, 2018: Synairgen: Interim results for the six months ended 30 June 2018 22

Mar 15, 2018: Synairgen: Preliminary statement of results for the year ended 31 December 2017 26

Sep 27, 2017: Synairgen: Interim results for the six months ended 30 June 2017 27

May 17, 2017: Synairgen Announces Preliminary statement of results for the year ended 31 December 2016 28

Product News 29

04/27/2017: Synairgen Provides Update On AZD9412 29

Mar 10, 2017: Synairgen: Additional Positive Data in Lung Fibrosis 30

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31


List Of Figure

List of Figures

Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Synairgen Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Synairgen Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Synairgen Plc, Deals By Therapy Area, 2012 to YTD 2018 8

Synairgen Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Pharmaxis Expands Agreement with Synairgen 10

AstraZeneca Enters into Licensing Agreement with Synairgen for SNG001 11

Synairgen to Raise USD3.7 Million in Private Placement of Shares 13

Synairgen Raises USD9 Million in Private Placement of Shares 15

Synairgen Announces Private Placement Of Shares For USD 2.5 Million 17

Synairgen Completes Private Placement Of Shares For USD 4 Million 18

Synairgen Plc, Key Competitors 19

Synairgen Plc, Key Employees 20

Synairgen Plc, Subsidiaries 21

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Synairgen Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-/SNG001) for asthma in Phase II trial; and IFN- (SNG001) for COPD in Phase I trial. The company develops its drugs based on its BioBank platform technology. Its BioBank comprises blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma and COPD. The company uses these resources to develop in vitro and ex vivo models, which can be used for discovering novel drug targets. It discovers and develops the drug targets through early stages and out-licenses them to other pharmaceutical companies for further development and manufacturing. Synairgen is headquartered at Southampton, the UK.

Synairgen Plc (SNG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Synairgen Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Synairgen Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Synairgen Plc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Pharmaxis Expands Agreement with Synairgen 10

Licensing Agreements 11

AstraZeneca Enters into Licensing Agreement with Synairgen for SNG001 11

Equity Offering 13

Synairgen to Raise USD3.7 Million in Private Placement of Shares 13

Synairgen Raises USD9 Million in Private Placement of Shares 15

Synairgen Announces Private Placement Of Shares For USD 2.5 Million 17

Synairgen Completes Private Placement Of Shares For USD 4 Million 18

Synairgen Plc-Key Competitors 19

Synairgen Plc-Key Employees 20

Synairgen Plc-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Recent Developments 22

Financial Announcements 22

Sep 25, 2018: Synairgen: Interim results for the six months ended 30 June 2018 22

Mar 15, 2018: Synairgen: Preliminary statement of results for the year ended 31 December 2017 26

Sep 27, 2017: Synairgen: Interim results for the six months ended 30 June 2017 27

May 17, 2017: Synairgen Announces Preliminary statement of results for the year ended 31 December 2016 28

Product News 29

04/27/2017: Synairgen Provides Update On AZD9412 29

Mar 10, 2017: Synairgen: Additional Positive Data in Lung Fibrosis 30

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31


List Of Figure

List of Figures

Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Synairgen Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Synairgen Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Synairgen Plc, Deals By Therapy Area, 2012 to YTD 2018 8

Synairgen Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Pharmaxis Expands Agreement with Synairgen 10

AstraZeneca Enters into Licensing Agreement with Synairgen for SNG001 11

Synairgen to Raise USD3.7 Million in Private Placement of Shares 13

Synairgen Raises USD9 Million in Private Placement of Shares 15

Synairgen Announces Private Placement Of Shares For USD 2.5 Million 17

Synairgen Completes Private Placement Of Shares For USD 4 Million 18

Synairgen Plc, Key Competitors 19

Synairgen Plc, Key Employees 20

Synairgen Plc, Subsidiaries 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Synairgen Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.